YACHARTER YANG: Open Payments
NPI 1548327190 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,592 in 99 payments from 12 companies in 2025. Trend: 2023 $1,106 · 2024 $1,912 · 2025 $3,592
Food & beverage: $2,598Consulting: $740Travel & lodging: $143Education: $111
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $1,464 |
| Janssen Pharmaceuticals, Inc | 11 | $339 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $275 |
| Neurocrine BioSciences, Inc. | 8 | $255 |
| Otsuka America Pharmaceutical, Inc. | 10 | $239 |
| Lilly USA, LLC | 8 | $235 |
| Alkermes, Inc. | 7 | $223 |
| Teva Pharmaceuticals USA, Inc. | 13 | $214 |
| Intra-Sana Laboratories | 5 | $119 |
| ABBVIE INC. | 4 | $94 |
Products named: COBENFY, INVEGA SUSTENNA, CAPLYTA, INGREZZA, VIVITROL, REXULTI, RELTONE 200 MG, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
